Analyst Price Target is $7.00
▲ +875.34% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Brooklyn ImmunoTherapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 875.34% upside from the last price of $0.72.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Brooklyn ImmunoTherapeutics.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.